{
  "docId": "019de076-87a3-715f-b988-6da9cfb3fd56",
  "docSlug": "560176b410a72a6b2e67af5dd2a20758",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 33,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "timeline",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a chevron-based timeline to distinguish between past achievements (checkmarks) and future goals (dots).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/29",
  "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56",
  "deckJsonHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56.json",
  "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.29
      },
      "kind": "diagram",
      "text": "2022, 2023, 2024",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1571609d-119f-4346-a2e7-16c8065505e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.67,
        "y": 0.45
      },
      "kind": "list",
      "text": "Neurofilament Results (Jan 2024); Biomarker Results (H1 2024); ALS End of Phase 2 Meeting with the FDA and EMA; Initiate ALS Phase 3 clinical study as needed",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e2eb4c8-12e4-45a8-b04f-c31e72cbdde4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.36,
        "y": 0.45
      },
      "kind": "list",
      "text": "Completed Alzheimer's biomarker study with positive results; Completed Parkinson's biomarker study with positive results; Type D Meeting with the FDA; Release ALS Phase 2b clinical study top-line results; Initiate Alzheimer's Phase 2 study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ef8b579-46af-4742-ab08-cee6cded908f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.04,
        "y": 0.45
      },
      "kind": "list",
      "text": "Initiated ALS Phase 2b PARADIGM study; Received FDA IND Clearance for PrimeC; Completed PK study single-dose & multi-dose successfully; Completed In-life 90-day GLP toxicology study successfully",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a807f54-2ed4-4242-a30e-f2bb0bee2010",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "Milestones Achieved and Upcoming Potential Catalysts",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ee49ccd-729a-4eec-acd0-063e3a488a05",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "9c0afef6-43ca-46d9-b54e-fc5d4f28eee0",
      "evidence": "Chronological progression of company events across three years.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 30,
      "from": 29,
      "beatId": "128bec34-fbcc-431e-ab02-89ccb10153a9",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document concludes by highlighting the potential impact of PrimeC and next steps for the company.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}